Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Geron Corp (GERN)

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 337,506
  • Shares Outstanding, K 203,317
  • Annual Sales, $ 460 K
  • Annual Income, $ -68,550 K
  • 60-Month Beta 1.68
  • Price/Sales 760.23
  • Price/Cash Flow N/A
  • Price/Book 2.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +4.40%
on 07/31/20
2.2674 -26.79%
on 07/07/20
-0.4700 (-22.07%)
since 07/06/20
3-Month
1.2300 +34.96%
on 05/07/20
2.4000 -30.83%
on 05/18/20
+0.4200 (+33.87%)
since 05/06/20
52-Week
0.7500 +121.33%
on 03/16/20
2.4000 -30.83%
on 05/18/20
+0.4700 (+39.50%)
since 08/06/19

Most Recent Stories

More News
Geron: 2Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $15.8 million in its second quarter.

GERN : 1.6600 (-3.49%)
Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today...

GERN : 1.6600 (-3.49%)
Geron to Present at the BTIG Virtual Biotechnology Conference

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat...

GERN : 1.6600 (-3.49%)
Geron to Announce Second Quarter Financial Results on August 6, 2020

Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available...

GERN : 1.6600 (-3.49%)
Geron Sees Hammer Chart Pattern: Time to Buy?

Geron has been struggling lately, but the selling pressure may be coming to an end soon

GERN : 1.6600 (-3.49%)
Geron Sees Hammer Chart Pattern: Time to Buy?

Geron has been struggling lately, but the selling pressure may be coming to an end soon.

GERN : 1.6600 (-3.49%)
Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?

Is (GERN) Outperforming Other Medical Stocks This Year?

GERN : 1.6600 (-3.49%)
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired employee...

GERN : 1.6600 (-3.49%)
Zealand Announces Dosing Initiation in Type 2 Diabetes Study

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.

ALXN : 103.90 (+1.12%)
GERN : 1.6600 (-3.49%)
AGTC : 5.35 (-2.73%)
ZEAL : 34.55 (-1.71%)
Geron's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Geron.

GERN : 1.6600 (-3.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GERN with:

Business Summary

Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking...

See More

Key Turning Points

2nd Resistance Point 1.8067
1st Resistance Point 1.7333
Last Price 1.6600
1st Support Level 1.6133
2nd Support Level 1.5667

See More

52-Week High 2.4000
Fibonacci 61.8% 1.7697
Last Price 1.6600
Fibonacci 50% 1.5750
Fibonacci 38.2% 1.3803
52-Week Low 0.7500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar